This is huge client to have . I am sure people can find info on what the company does. The main bread and butter for ABMD are the Impella Devices . Version 2.5 and 5 ( based on amount of blood flow ) are well entrenched in the PCT sector and have huge market share
However here is some info I think that is specific to Sensera.
Impella RP
They have recently got PMA FDA approval for their Impella RP ( only device for right side of the heart support ) and it's a game changer. I suspect that will be the first device to come onboard. I think the company alluded to that in yesterday's announcement.
View attachment 827618
Impella RP product launch post FDA PMA approval appears to be on track.
Based on research, company is on track for commercial launch by 31 March 2018.
Product already introduced to the market
At the end of first half 2017, Abiomed had placed Impella RP, a percutaneous catheter-based axial flow pump currently under review of the FDA in 160 hospitals. Now, after securing PMA (post-marketing approval) for this device, the company plans to place the device in around 1,000 sites.
Abiomed has already been demonstration the product to about 300 hospitals as of March 2017 and plan to increase exposure to 1000
View attachment 827621
How fast will be the sales ??
Abiomed has also opted for a PMA pathway to launch Impella RP, instead of choosing to launch the device under a humanitarian device exemption. In the latter case, hospitals would have been required to sign up with the Institutional Review Board (or IRB) to use the device.
The PMA pathway will ensure faster penetration of the device, which is expected to target ~1,000 hospital sites in future years. In addition to heart hospitals with cath labs and surgical suites, which would require biventricular support, 400 more heart hospitals with only cath labs may also have to be equipped to provide biventricular support before shifting patients to major sites. This dynamic could further fuel additional demand for Impella RP.
Standard surgery and devices costs around $20,000.
Future plans for Impella
In fiscal 2018, *
the company plans to invest in enhancing its existing product lines* by adding sensing technologies and entering new med-tech markets such as Japan. The company aims to expand the label of its Impella CP device in patients with STEMI (ST segment elevation myocardial infarction) prior to PCI (primary percutaneous coronary intervention) procedures in fiscal 2018.
Abiomed also plans to release new products including ECP 5.5, Impella 55, and Impella BTR in fiscal 2018.
View attachment 827642
The company makes $500 mil per annum from these devices and Sensera is well entrenched into their supply chain. Don't forget besides providing mems Sensera is also doing assembly .
This is going to be a huge contract in the next 12-24 months and recurring with long runway for growth.
